Fox Run Management L.L.C. Buys Shares of 12,815 Omnicell, Inc. $OMCL

Key Points

• Fox Run Management L.L.C. invested approximately $448,000 in Omnicell, Inc., acquiring 12,815 shares of the company's stock in the first quarter.
• Analysts have varying outlooks on Omnicell's stock, with a current average target price of $46.71 and three hold ratings alongside five buy ratings.
• Omnicell reported a year-over-year revenue increase of 5.0% for the last quarter, with earnings per share of $0.45, exceeding expectations.

Fox Run Management L.L.C. purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 12,815 shares of the company's stock, valued at approximately $448,000.

Several other institutional investors and hedge funds also recently modified their holdings of OMCL. Public Sector Pension Investment Board raised its position in Omnicell by 27.6% in the 1st quarter. Public Sector Pension Investment Board now owns 146,916 shares of the company's stock valued at $5,136,000 after buying an additional 31,765 shares during the last quarter. Nuveen LLC bought a new position in shares of Omnicell during the 1st quarter worth approximately $6,218,000. Invesco Ltd. grew its stake in shares of Omnicell by 1.9% during the 1st quarter. Invesco Ltd. now owns 223,629 shares of the company's stock worth $7,818,000 after acquiring an additional 4,176 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Omnicell by 5.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 453,988 shares of the company's stock valued at $15,871,000 after purchasing an additional 24,301 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Omnicell by 4.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock worth $553,000 after purchasing an additional 696 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

Omnicell stock traded up $1.73 during midday trading on Friday, reaching $33.62. 863,923 shares of the company's stock were exchanged, compared to its average volume of 641,752. The stock's 50-day simple moving average is $29.62 and its 200 day simple moving average is $31.78. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 67.24, a P/E/G ratio of 9.81 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same period last year, the firm posted $0.51 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of analyst reports. Bank of America raised their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Benchmark lowered their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company increased their price target on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.71.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.